These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2767107)

  • 41. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
    Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
    Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
    Keskin A; Tombuloğlu M; Atamer MA; Büyükkeçeci F
    Acta Haematol; 1994; 92(1):14-7. PubMed ID: 7985476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy-induced acral erythema due to Tegafur.
    Bastida J; Díaz-Cascajo C; Borghi S
    Acta Derm Venereol; 1997 Jan; 77(1):72-3. PubMed ID: 9059686
    [No Abstract]   [Full Text] [Related]  

  • 45. Diagnosis in oncology. Hand-foot syndrome.
    Jucgla A; Sais G
    J Clin Oncol; 1997 Sep; 15(9):3164. PubMed ID: 9312563
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy.
    Cox GJ; Robertson DB
    Arch Dermatol; 1986 Dec; 122(12):1413-4. PubMed ID: 2947543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Possibilities for the cure of acute myeloblastic leukemia with the modified VAPA regimen: preliminary results].
    Díaz Mediavilla J; del Potro Gómez E; Llorente Pérez L; Martínez Martínez R; Guerra Moyano JL; de la Vega Bueno E; Alvarez Carmona A; Krsnik Castelló I; Alarcón Zurita C; Rodríguez Vázquez M
    Med Clin (Barc); 1984 Dec; 83(19):783-6. PubMed ID: 6597329
    [No Abstract]   [Full Text] [Related]  

  • 50. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
    Walters RS; Kantarjian HM; Keating MJ; Plunkett WK; Estey EH; Andersson B; Beran M; McCredie KB; Freireich EJ
    Cancer; 1988 Aug; 62(4):677-82. PubMed ID: 3165047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD; How C; Harrold K
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
    Zhong LY; Li QH; Huang ZL; Lin W; Lu ZS; Weng JY; Wu SJ; Du X
    Ai Zheng; 2009 Jun; 28(6):619-25. PubMed ID: 19635200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
    Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
    Lei M; Liu L; Wang Z; Wu D
    Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
    Dekker AW; Nieuwenhuis HK; Verdonck LF
    Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.